Ghrp-6
GHRP-6 is a synthetic hexapeptide belonging to the “growth hormone secretagogues” (GHS), studied for its ability to acutely stimulate the release of growth hormone (GH) and, to a variable extent, increase appetite through activation of the ghrelin receptor. It is neither an essential nutrient nor a traditional dietary supplement; its use is primarily experimental/research-based and involves significant safety and regulatory considerations.
Growth hormone (GH) secretagogue peptide with agonist activity at the ghrelin receptor (GHS-R1a)
GHRP-6 is a synthetic hexapeptide belonging to the “growth hormone secretagogues” (GHS), studied for its ability to acutely stimulate the release of growth hormone (GH) and, to a variable extent, to increase appetite through activation of the ghrelin receptor. It is neither an essential nutrient nor a traditional dietary supplement; its use is primarily experimental/research-based and involves significant safety and regulatory considerations.
Mechanism of action
GHRP-6 is an agonist of the GH secretagogue receptor (GHS-R1a), the same receptor activated by ghrelin. Activation of GHS-R1a at the hypothalamic and pituitary level increases pulsatile GH secretion. The mechanism is partly synergistic with GHRH (growth hormone releasing hormone) and may reduce somatostatin-mediated inhibition. The increase in GH may lead to a rise in IGF-1 (somatomedin C) over time, but the magnitude depends on dose, frequency, nutritional status, age, and individual sensitivity. Activation of the ghrelin pathway may also modulate appetite, gastrointestinal motility, and neuroendocrine signals (with possible changes in prolactin and cortisol).
Supported benefits
- Acute and measurable increase in GH secretion (pulsatile response) in experimental settings (strong)
- Possible increase in appetite (orexigenic effect) consistent with GHS-R1a agonism (moderate)
- Increase in IGF-1 with repeated administrations in some experimental protocols (dependent on regimen and population) (limited)
- Potential utility as a diagnostic/research tool for evaluating somatotropic reserve (GH stimulation test) in experimental settings (moderate)
Safety & side effects
- Increased appetite (orexigenic effect), sometimes marked
- Hot flashes/flushing, headache, dizziness (reported with other GH secretagogues and in experimental settings)
- Nausea or gastrointestinal disturbances
- Fluid retention/edema and paresthesias: possibly indirectly through increased GH/IGF-1 in some individuals
- Increase in prolactin and/or ACTH/cortisol in some protocols: potential effects on mood, sleep, metabolism, and blood pressure
- Local reactions at the injection site (pain, redness, infection) if administered parenterally
- Possible alterations in blood glucose (GH is counterregulatory to insulin): theoretical risk of worsening insulin sensitivity in some contexts
FAQ
Is GHRP-6 the same thing as GH (growth hormone)?
No. GH is a protein hormone produced by the pituitary gland (or administered as a drug). GHRP-6 is a peptide that stimulates endogenous GH secretion by activating the ghrelin receptor (GHS-R1a), generating a pulsatile and transient increase.
Does increasing GH automatically mean increasing muscle mass and performance?
Not necessarily. An acute increase in GH does not automatically translate into improvements in strength or performance. The effects on body composition and performance depend on many variables, and the evidence in healthy subjects is limited.
Why can GHRP-6 increase appetite?
Because it acts on the ghrelin receptor (GHS-R1a), which is involved in the regulation of hunger and orexigenic signals at the central level.
What are the main endocrine risks?
In addition to GH, prolactin and ACTH/cortisol may increase in some individuals/protocols, with possible effects on metabolism, fluid retention, sleep, and psychological well-being. In addition, the GH/IGF-1 axis can influence blood glucose regulation.
Is it detectable in anti-doping tests?
GH secretagogues are prohibited in sport. Detection strategies may include targeted analyses and indirect assessments of the GH/IGF-1 axis depending on the protocols and substances involved; the details depend on the laboratory methods and the rules in force.
The information provided is for informational and educational purposes only. It does not constitute medical advice. Use must be evaluated and authorized by a qualified healthcare professional.
Mechanism of action
GHRP-6 is an agonist of the GH secretagogue receptor (GHS-R1a), the same receptor activated by ghrelin. Activation of GHS-R1a at the hypothalamic and pituitary level increases pulsatile GH secretion. The mechanism is partly synergistic with GHRH (growth hormone releasing hormone) and may reduce somatostatin-mediated inhibition. The increase in GH may lead to an increase in IGF-1 (somatomedin C) over time, but the extent depends on dose, frequency, nutritional status, age, and individual sensitivity. Activation of the ghrelin pathway may also modulate appetite, gastrointestinal motility, and neuroendocrine signals (with possible variations in prolactin and cortisol).
Scientific benefits
Contraindications
- Pregnancy and breastfeeding (lack of adequate safety data)
- Pediatric age outside controlled clinical settings
- Active or suspected neoplasms: the GH/IGF-1 axis is involved in cell proliferation; high caution is warranted in the absence of a medical indication
- Uncontrolled diabetes or conditions with glycemic instability
- Unevaluated pituitary/hypothalamic disorders (risk of interfering with diagnosis/monitoring)
- Untreated obstructive sleep apnea or conditions in which fluid retention could worsen symptoms (clinical evaluation required)
Side effects
- Increased appetite (orexigenic), sometimes marked
- Hot flashes/flushing, headache, dizziness (reported with other GH secretagogues and in experimental settings)
- Nausea or gastrointestinal disturbances
- Fluid retention/edema and paresthesias: possible indirectly through increased GH/IGF-1 in some individuals
- Increase in prolactin and/or ACTH/cortisol in some protocols: potential effects on mood, sleep, metabolism, and blood pressure
- Local reactions at the injection site (pain, redness, infection) if administered parenterally
- Possible alterations in blood glucose (GH is counterregulatory to insulin): theoretical risk of worsening insulin sensitivity in some contexts
Interactions
- Drugs that affect blood glucose (insulin, glucose-lowering agents): possible need for clinical monitoring for changes in glycemic response
- Glucocorticoids: may modulate the GH axis and the response to stimulation; in addition, GHRP-6 may influence ACTH/cortisol in some individuals
- Dopaminergic/antidopaminergic agents: potential indirect interaction via prolactin (since some secretagogues may increase it)
- Other agents that increase GH/IGF-1: possible additive effects and risks (fluid retention, metabolic alterations)
Regulatory status
In many jurisdictions, GHRP-6 is not approved as a drug for standard clinical indications and is not authorized as a dietary supplement. It is commonly classified as a prohibited substance in anti-doping contexts (GH secretagogue). Specific legal status depends on the country and local regulations on drugs/research peptides.
Supplements and peptides
PeptidesBpc-157
BPC-157 is a 15-amino-acid peptide derived from a sequence present in gastric juice (BPC). It is the subject of…
PeptidesCjc-1295
CJC-1295 is a peptide designed to stimulate the pulsatile secretion of growth hormone (GH) through activation of the…
PeptidesDsip
DSIP (Delta Sleep-Inducing Peptide) is a peptide originally described for its possible ability to modulate sleep…